1
|
Strullu M, Cousin E, de Montgolfier S, Fenwarth L, Gachard N, Arnoux I, Duployez N, Girard S, Guilmatre A, Lafage M, Loosveld M, Petit A, Perrin L, Vial Y, Saultier P. [Suspicion of constitutional abnormality at diagnosis of childhood leukemia: Update of the leukemia committee of the French Society of Childhood Cancers]. Bull Cancer 2024; 111:291-309. [PMID: 38267311 DOI: 10.1016/j.bulcan.2023.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 11/06/2023] [Accepted: 11/17/2023] [Indexed: 01/26/2024]
Abstract
The spectrum of childhood leukemia predisposition syndromes has grown significantly over last decades. These predisposition syndromes mainly involve CEBPA, ETV6, GATA2, IKZF1, PAX5, RUNX1, SAMD9/SAMD9L, TP53, RAS-MAPK pathway, DNA mismatch repair system genes, genes associated with Fanconi anemia, and trisomy 21. The clinico-biological features leading to the suspicion of a leukemia predisposition are highly heterogeneous and require varied exploration strategies. The study of the initial characteristics of childhood leukemias includes high-throughput sequencing techniques, which have increased the frequency of situations where a leukemia predisposing syndrome is suspected. Identification of a leukemia predisposition syndrome can have a major impact on the choice of chemotherapy, the indication for hematopoietic stem cell transplantation, and screening for associated malformations and pathologies. The diagnosis of a predisposition syndrome can also lead to the exploration of family members and genetic counseling. Diagnosis and management should be based on dedicated and multidisciplinary care networks.
Collapse
Affiliation(s)
- Marion Strullu
- Hématologie et immunologie pédiatrique, hôpital Robert-Debré, GHU AP-HP Nord-Université Paris Cité, Paris, France; Inserm UMR_S1131, Institut universitaire d'hématologie, université Paris Cité, Paris cité, Paris, France.
| | - Elie Cousin
- Service d'onco-hématologie pédiatrique, CHU de Rennes, Rennes, France
| | - Sandrine de Montgolfier
- Aix Marseille université, Inserm, IRD, SESSTIM, sciences économiques & sociales de la santé & traitement de l'information médicale, ISSPAM, Marseille, France
| | - Laurene Fenwarth
- Département de génétique clinique, laboratoire d'hématologie, unité de génétique moléculaire des hémopathies malignes, CHU de Lille, université de Lille, Lille, France
| | | | | | - Nicolas Duployez
- Laboratoire d'hématologie, unité de génétique moléculaire des hémopathies malignes, CHU de Lille, université de Lille, Lille, France
| | - Sandrine Girard
- Service d'hématologie biologique, centre de biologie et pathologie Est, LBMMS, hospices civils de Lyon, Lyon, France
| | - Audrey Guilmatre
- Service d'hématologie et oncologie pédiatrique, hôpital Armand-Trousseau, AP-HP.Sorbonne Université, Paris, France
| | - Marina Lafage
- CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille université U105, laboratoire d'hématologie, CHU Timone, Marseille, France
| | - Marie Loosveld
- CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille université U105, laboratoire d'hématologie, CHU Timone, Marseille, France
| | - Arnaud Petit
- Service d'hématologie et oncologie pédiatrique, hôpital Armand-Trousseau, AP-HP.Sorbonne Université, Paris, France
| | - Laurence Perrin
- Génétique clinique, hôpital Robert-Debré, GHU AP-HP Nord-Université Paris cité, Paris, France
| | - Yoan Vial
- Inserm UMR_S1131, Institut universitaire d'hématologie, université Paris Cité, Paris cité, Paris, France; Laboratoire de génétique moléculaire, hôpital Robert-Debré, GHU AP-HP Nord-Université Paris cité, Paris, France
| | - Paul Saultier
- Service d'hématologie immunologie oncologie pédiatrique, Inserm, INRAe, C2VN, hôpital d'Enfants de la Timone, Aix Marseille université, AP-HM, Marseille, France
| |
Collapse
|
2
|
Quessada J, Loosveld M. CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia. Blood 2023; 142:2332. [PMID: 38153768 DOI: 10.1182/blood.2023022090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2023] Open
|
3
|
Fontenaille C, De Sainte Marie B, Loosveld M, Ebbo M, Schleinitz N. Dramatic response to intravenous immunoglobulin in erythroblastic synartesis. Br J Haematol 2023; 203:886-888. [PMID: 37691168 DOI: 10.1111/bjh.19098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 08/09/2023] [Accepted: 08/25/2023] [Indexed: 09/12/2023]
Affiliation(s)
- Clara Fontenaille
- Department of Internal Medicine, Timone's Hospital, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille Université (AMU), Marseille, France
| | - Benjamin De Sainte Marie
- Department of Internal Medicine, Timone's Hospital, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille Université (AMU), Marseille, France
| | - Marie Loosveld
- Department of Biological Haematology, Timone's Hospital, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille Université (AMU), Marseille, France
| | - Mikael Ebbo
- Department of Internal Medicine, Timone's Hospital, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille Université (AMU), Marseille, France
| | - Nicolas Schleinitz
- Department of Internal Medicine, Timone's Hospital, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille Université (AMU), Marseille, France
| |
Collapse
|
4
|
Quessada J, Petit A, Saultier P, Fenwarth L, Marceau-Renaut A, Arnoux I, Payet-Bornet D, Michel G, Lafage M, Loosveld M. Diagnostic challenge in a case of ambiguous lineage acute leukemia with PICALM::MLLT10 rearrangement. Pediatr Blood Cancer 2023; 70:e30573. [PMID: 37439579 DOI: 10.1002/pbc.30573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 06/30/2023] [Accepted: 07/04/2023] [Indexed: 07/14/2023]
Affiliation(s)
- Julie Quessada
- Département d'Hématologie, APHM, Hôpital La Timone, Marseille, France
- CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes, Marseille, France
| | - Audrey Petit
- Département d'Hématologie et d'Oncologie Pédiatrique, APHM, Hôpital La Timone, Marseille, France
| | - Paul Saultier
- Département d'Hématologie et d'Oncologie Pédiatrique, APHM, Hôpital La Timone, Marseille, France
- Aix Marseille Université, INSERM, INRA, C2VN, Marseille, France
| | - Laurène Fenwarth
- Laboratoire Hématologie, Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France
- U1277 Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), University of Lille, INSERM, Lille, France
| | - Alice Marceau-Renaut
- Laboratoire Hématologie, Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France
- U1277 Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), University of Lille, INSERM, Lille, France
| | - Isabelle Arnoux
- Département d'Hématologie, APHM, Hôpital La Timone, Marseille, France
| | - Dominique Payet-Bornet
- CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes, Marseille, France
| | - Gérard Michel
- Département d'Hématologie et d'Oncologie Pédiatrique, APHM, Hôpital La Timone, Marseille, France
| | - Marina Lafage
- Département d'Hématologie, APHM, Hôpital La Timone, Marseille, France
| | - Marie Loosveld
- Département d'Hématologie, APHM, Hôpital La Timone, Marseille, France
- CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes, Marseille, France
| |
Collapse
|
5
|
Bigot T, Gabinaud E, Hannouche L, Sbarra V, Andersen E, Bastelica D, Falaise C, Bernot D, Ibrahim-Kosta M, Morange PE, Loosveld M, Saultier P, Payet-Bornet D, Alessi MC, Potier D, Poggi M. Single-cell analysis of megakaryopoiesis in peripheral CD34 + cells: insights into ETV6-related thrombocytopenia. J Thromb Haemost 2023; 21:2528-2544. [PMID: 37085035 DOI: 10.1016/j.jtha.2023.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 03/21/2023] [Accepted: 04/04/2023] [Indexed: 04/23/2023]
Abstract
BACKGROUND Germline mutations in the ETV6 transcription factor gene are responsible for familial thrombocytopenia and leukemia predisposition syndrome. Although previous studies have shown that ETV6 plays an important role in megakaryocyte (MK) maturation and platelet formation, the mechanisms by which ETV6 dysfunction promotes thrombocytopenia remain unclear. OBJECTIVES To decipher the transcriptional mechanisms and gene regulatory network linking ETV6 germline mutations and thrombocytopenia. METHODS Presuming that ETV6 mutations result in selective effects at a particular cell stage, we applied single-cell RNA sequencing to understand gene expression changes during megakaryopoiesis in peripheral CD34+ cells from healthy controls and patients with ETV6-related thrombocytopenia. RESULTS Analysis of gene expression and regulon activity revealed distinct clusters partitioned into 7 major cell stages: hematopoietic stem/progenitor cells, common-myeloid progenitors (CMPs), MK-primed CMPs, granulocyte-monocyte progenitors, MK-erythroid progenitors (MEPs), progenitor MKs/mature MKs, and platelet-like particles. We observed a differentiation trajectory in which MEPs developed directly from hematopoietic stem/progenitor cells and bypassed the CMP stage. ETV6 deficiency led to the development of aberrant cells as early as the MEP stage, which intensified at the progenitor MK/mature MK stage, with a highly deregulated core "ribosome biogenesis" pathway. Indeed, increased translation levels have been documented in patient CD34+-derived MKs with overexpression of ribosomal protein S6 and phosphorylated ribosomal protein S6 in both CD34+-derived MKs and platelets. Treatment of patient MKs with the ribosomal biogenesis inhibitor CX-5461 resulted in an increase in platelet-like particles. CONCLUSION These findings provide novel insight into both megakaryopoiesis and the link among ETV6, translation, and platelet production.
Collapse
Affiliation(s)
- Timothée Bigot
- Aix-Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | - Elisa Gabinaud
- Aix-Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | | | | | - Elisa Andersen
- Aix-Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | | | | | - Denis Bernot
- Aix-Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | | | | | - Marie Loosveld
- Aix-Marseille Univ, CNRS, INSERM, CIML, Marseille, France
| | - Paul Saultier
- Aix-Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | | | - Marie-Christine Alessi
- Aix-Marseille Univ, INSERM, INRAe, C2VN, Marseille, France; AP-HM, CHU Timone, CRPP, Marseille, France
| | | | - Marjorie Poggi
- Aix-Marseille Univ, INSERM, INRAe, C2VN, Marseille, France.
| |
Collapse
|
6
|
Combaluzier S, Loosveld M, Nivaggioni V. Detection of unstable haemoglobin variants with Sysmex XN-10. Int J Lab Hematol 2023; 45:e21-e23. [PMID: 36113870 DOI: 10.1111/ijlh.13967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 08/29/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Sophie Combaluzier
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Marie Loosveld
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France.,CNRS, INSERM, CIML, Aix Marseille University, Marseille, France
| | - Vanessa Nivaggioni
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| |
Collapse
|
7
|
Combaluzier S, Quessada J, Abbou N, Arcani R, Tichadou A, Gabert J, Costello R, Loosveld M, Venton G, Berda-Haddad Y. Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells 2023; 12:cells12060946. [PMID: 36980287 PMCID: PMC10047531 DOI: 10.3390/cells12060946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 03/14/2023] [Accepted: 03/16/2023] [Indexed: 03/30/2023] Open
Abstract
Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup BCR::ABL1-negative MPN. World Health Organization (WHO) classification of myeloid neoplasms evolves over the years and increasingly considers molecular abnormalities to prove the clonal hematopoiesis. In addition to morphological clues, the detection of JAK2, MPL and CALR mutations are considered driver events belonging to the major diagnostic criteria of BCR::ABL1-negative MPN. This highlights the preponderant place of molecular features in the MPN diagnosis. Moreover, the advent of next-generation sequencing (NGS) allowed the identification of additional somatic mutations involved in clonal hematopoiesis and playing a role in the prognosis of MPN. Nowadays, careful cytomorphology and molecular biology are inseparable and complementary to provide a specific diagnosis and to permit the best follow-up of these diseases.
Collapse
Affiliation(s)
- Sophie Combaluzier
- Hematology Laboratory, Timone University Hospital, 13005 Marseille, France
| | - Julie Quessada
- Hematological Cytogenetics Laboratory, Timone University Hospital, 13005 Marseille, France
- CNRS, INSERM, CIML, Luminy Campus, Aix-Marseille University, 13009 Marseille, France
| | - Norman Abbou
- Molecular Biology Laboratory, North University Hospital, 13015 Marseille, France
- INSERM, INRAE, C2VN, Luminy Campus, Aix-Marseille University, 13005 Marseille, France
| | - Robin Arcani
- INSERM, INRAE, C2VN, Luminy Campus, Aix-Marseille University, 13005 Marseille, France
- Department of Internal Medicine, Timone University Hospital, 13005 Marseille, France
| | - Antoine Tichadou
- Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France
| | - Jean Gabert
- Molecular Biology Laboratory, North University Hospital, 13015 Marseille, France
| | - Régis Costello
- INSERM, INRAE, C2VN, Luminy Campus, Aix-Marseille University, 13005 Marseille, France
- Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France
- TAGC, INSERM, UMR1090, Luminy Campus, Aix-Marseille University, 13005 Marseille, France
| | - Marie Loosveld
- Hematology Laboratory, Timone University Hospital, 13005 Marseille, France
- Hematological Cytogenetics Laboratory, Timone University Hospital, 13005 Marseille, France
- CNRS, INSERM, CIML, Luminy Campus, Aix-Marseille University, 13009 Marseille, France
| | - Geoffroy Venton
- INSERM, INRAE, C2VN, Luminy Campus, Aix-Marseille University, 13005 Marseille, France
- Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France
- TAGC, INSERM, UMR1090, Luminy Campus, Aix-Marseille University, 13005 Marseille, France
| | - Yaël Berda-Haddad
- Hematology Laboratory, Timone University Hospital, 13005 Marseille, France
| |
Collapse
|
8
|
Ait-Belkacem I, Cartagena García C, Millet-Wallisky E, Izquierdo N, Loosveld M, Arnoux I, Morange PE, Galland F, Lambert N, Malergue F, Busnel JM. SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity. Sci Rep 2022; 12:20824. [PMID: 36460710 PMCID: PMC9716544 DOI: 10.1038/s41598-022-25259-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 11/28/2022] [Indexed: 12/03/2022] Open
Abstract
A strong bias related to age is observed in COVID-19 patients with pediatric subjects developing a milder disease than adults. We hypothesized that a specific SARS-CoV-2 effect conjugated with preexisting differences in the immune systems may explain this. Using flow cytometry, we investigated basal immune differences in a cohort consisting of 16 non-infected young and 16 aged individuals and further leveraged an in vitro whole blood model of SARS-CoV-2 infection so that functional differences could be mined as well. In short, blood diluted in culture media was incubated 5 or 24 h with the trimeric spike protein or controls. Following unsupervised analysis, we first confirmed that the immune lymphoid and myeloid systems in adults are less efficient and prone to develop higher inflammation than those in children. We notably identified in adults a higher CD43 lymphocyte expression, known for its potentially inhibitory role. The spike protein induced different responses between adults and children, notably a higher increase of inflammatory markers together with lower monocyte and B cell activation in adults. Interestingly, CD169, a CD43 ligand overexpressed in COVID-19 patients, was confirmed to be strongly modulated by the spike protein. In conclusion, the spike protein exacerbated the preexisting lower immune responsiveness and higher inflammatory potential in adults. Altogether, some of the markers identified may explain the marked age bias and be predictive of severity.
Collapse
Affiliation(s)
- Ines Ait-Belkacem
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France ,grid.417850.f0000 0004 0639 5277Aix Marseille Université CNRS INSERM CIML Centre d’Immunologie de Marseille-Luminy, Marseille, France
| | - Celia Cartagena García
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France ,grid.5399.60000 0001 2176 4817INSERM UMRs 1097, Aix Marseille University, Marseille, France
| | - Ewa Millet-Wallisky
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France
| | - Nicolas Izquierdo
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France
| | - Marie Loosveld
- grid.411266.60000 0001 0404 1115Hematology Laboratory, Timone University Hospital, APHM, Marseille, France
| | - Isabelle Arnoux
- grid.411266.60000 0001 0404 1115Hematology Laboratory, Timone University Hospital, APHM, Marseille, France
| | - Pierre-Emmanuel Morange
- grid.411266.60000 0001 0404 1115Hematology Laboratory, Timone University Hospital, APHM, Marseille, France
| | - Franck Galland
- grid.417850.f0000 0004 0639 5277Aix Marseille Université CNRS INSERM CIML Centre d’Immunologie de Marseille-Luminy, Marseille, France
| | - Nathalie Lambert
- grid.5399.60000 0001 2176 4817INSERM UMRs 1097, Aix Marseille University, Marseille, France
| | - Fabrice Malergue
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France
| | - Jean-Marc Busnel
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France
| |
Collapse
|
9
|
Pankaew S, Potier D, Grosjean C, Nozais M, Quessada J, Loosveld M, Remy É, Payet-Bornet D. Calcium Signaling Is Impaired in PTEN-Deficient T Cell Acute Lymphoblastic Leukemia. Front Immunol 2022; 13:797244. [PMID: 35185889 PMCID: PMC8847596 DOI: 10.3389/fimmu.2022.797244] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 01/17/2022] [Indexed: 11/13/2022] Open
Abstract
PTEN (Phosphatase and TENsin homolog) is a well-known tumor suppressor involved in numerous types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL). In human, loss-of-function mutations of PTEN are correlated to mature T-ALL expressing a T-cell receptor (TCR) at their cell surface. In accordance with human T-ALL, inactivation of Pten gene in mouse thymocytes induces TCRαβ+ T-ALL development. Herein, we explored the functional interaction between TCRαβ signaling and PTEN. First, we performed single-cell RNA sequencing (scRNAseq) of PTEN-deficient and PTEN-proficient thymocytes. Bioinformatic analysis of our scRNAseq data showed that pathological Ptendel thymocytes express, as expected, Myc transcript, whereas inference of pathway activity revealed that these Ptendel thymocytes display a lower calcium pathway activity score compared to their physiological counterparts. We confirmed this result using ex vivo calcium flux assay and showed that upon TCR activation tumor Ptendel blasts were unable to release calcium ions (Ca2+) from the endoplasmic reticulum to the cytosol. In order to understand such phenomena, we constructed a mathematical model centered on the mechanisms controlling the calcium flux, integrating TCR signal strength and PTEN interactions. This qualitative model displays a dynamical behavior coherent with the dynamics reported in the literature, it also predicts that PTEN affects positively IP3 (inositol 1,4,5-trisphosphate) receptors (ITPR). Hence, we analyzed Itpr expression and unraveled that ITPR proteins levels are reduced in PTEN-deficient tumor cells compared to physiological and leukemic PTEN-proficient cells. However, calcium flux and ITPR proteins expression are not defective in non-leukemic PTEN-deficient T cells indicating that beyond PTEN loss an additional alteration is required. Altogether, our study shows that ITPR/Calcium flux is a part of the oncogenic landscape shaped by PTEN loss and pinpoints a putative role of PTEN in the regulation of ITPR proteins in thymocytes, which remains to be characterized.
Collapse
Affiliation(s)
- Saran Pankaew
- Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.,Aix Marseille Univ, CNRS, I2M, Marseille, France
| | | | | | - Mathis Nozais
- Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France
| | - Julie Quessada
- Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France
| | - Marie Loosveld
- Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.,APHM, Hôpital La Timone, Laboratoire d'Hématologie, Marseille, France
| | | | | |
Collapse
|
10
|
Legland Ép Dejean AM, Plantamura J, Arnoux I, Paleiron N, Loosveld M, Buono Ép Foucher B. Acanthocytosis in an alectinib-treated patient. Br J Haematol 2022; 197:131. [PMID: 35128635 DOI: 10.1111/bjh.18020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/09/2021] [Accepted: 12/13/2021] [Indexed: 11/30/2022]
Affiliation(s)
| | | | - Isabelle Arnoux
- Laboratoire d'Hématologie, Hopital de la Timone, Marseille, France
| | | | - Marie Loosveld
- Laboratoire d'Hématologie, Hopital de la Timone, Marseille, France
| | | |
Collapse
|
11
|
Pankaew S, Grosjean C, Quessada J, Loosveld M, Potier D, Payet-Bornet D, Nozais M. Multiplexed single-cell RNA-sequencing of mouse thymic and splenic samples. STAR Protoc 2021; 3:101041. [PMID: 36475567 PMCID: PMC9698364 DOI: 10.1016/j.xpro.2021.101041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 10/26/2021] [Accepted: 11/22/2021] [Indexed: 12/14/2022] Open
Abstract
Multiplexed single-cell RNA-sequencing (scRNA-seq) enables investigating several biological samples in one scRNA-seq experiment. Here, we use antibodies tagged with a hashtag oligonucleotide (Ab-HTO) to label each sample, and 10× Genomics technology to analyze single-cell gene expression. Advantages of sample multiplexing are to reduce the cost of scRNA-seq assay and to avoid batch effect. It may also facilitate cell-doublet removal and the merging of several scRNA-seq assays. Herein, we apply multiplexed scRNA-seq to investigate mouse thymocytes and splenic T lymphocytes development. For complete details on the use and execution of this protocol, please refer to Nozais et al. (2021).
Collapse
Affiliation(s)
- Saran Pankaew
- Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille Cedex 9, France
| | - Clémence Grosjean
- Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille Cedex 9, France
| | - Julie Quessada
- Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille Cedex 9, France
| | - Marie Loosveld
- Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille Cedex 9, France; APHM, Hôpital La Timone, Laboratoire d'Hématologie, Marseille, France
| | - Delphine Potier
- Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille Cedex 9, France
| | - Dominique Payet-Bornet
- Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille Cedex 9, France.
| | - Mathis Nozais
- Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille Cedex 9, France.
| |
Collapse
|
12
|
Grosjean C, Quessada J, Nozais M, Loosveld M, Payet-Bornet D, Mionnet C. Isolation and enrichment of mouse splenic T cells for ex vivo and in vivo T cell receptor stimulation assays. STAR Protoc 2021; 2:100961. [PMID: 34825221 PMCID: PMC8605083 DOI: 10.1016/j.xpro.2021.100961] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Specific antigen recognition by T cell receptor (TCR) activates TCR signaling pathway, leading to T cell proliferation and differentiation into effector and memory cells. Herein, we describe protocols for TCR stimulation assays, including procedures for the isolation and enrichment of mouse splenic T cells for ex vivo TCR stimulation with anti-CD3/CD28 antibodies, and the use of ovalbumin-OT-II mouse model for in vivo TCR stimulation. We applied this protocol to show that MYC protein is essential for T cell proliferation and differentiation. For complete details on the use and execution of this protocol, please refer to Nozais et al. (2021). Isolation and enrichment of T cells from mouse spleen Ex vivo T cell receptor stimulation with anti-CD3/CD28 antibodies In vivo T cell receptor stimulation using ovalbumin-OT-II mouse model Analysis of TCR-induced T cell proliferation
Collapse
Affiliation(s)
- Clémence Grosjean
- Aix Marseille Univ, CNRS, Inserm, Centre d'immunologie de Marseille-Luminy (CIML), Parc Scientifique de Luminy, Case 906, 13 288 Marseille Cedex 9, France
| | - Julie Quessada
- Aix Marseille Univ, CNRS, Inserm, Centre d'immunologie de Marseille-Luminy (CIML), Parc Scientifique de Luminy, Case 906, 13 288 Marseille Cedex 9, France
| | - Mathis Nozais
- Aix Marseille Univ, CNRS, Inserm, Centre d'immunologie de Marseille-Luminy (CIML), Parc Scientifique de Luminy, Case 906, 13 288 Marseille Cedex 9, France
| | - Marie Loosveld
- Aix Marseille Univ, CNRS, Inserm, Centre d'immunologie de Marseille-Luminy (CIML), Parc Scientifique de Luminy, Case 906, 13 288 Marseille Cedex 9, France.,APHM, Hospital La Timone, Laboratoire d'Hématologie, Marseille, France
| | - Dominique Payet-Bornet
- Aix Marseille Univ, CNRS, Inserm, Centre d'immunologie de Marseille-Luminy (CIML), Parc Scientifique de Luminy, Case 906, 13 288 Marseille Cedex 9, France
| | - Cyrille Mionnet
- Aix Marseille Univ, CNRS, Inserm, Centre d'immunologie de Marseille-Luminy (CIML), Parc Scientifique de Luminy, Case 906, 13 288 Marseille Cedex 9, France
| |
Collapse
|
13
|
Nivaggioni V, Van Mirre E, Brousseau J, Loosveld M. Detection of Southern Asian Ovalocytosis with Sysmex XN-10: A complement to the decision tree previously described. Int J Lab Hematol 2021; 44:e84-e86. [PMID: 34664395 DOI: 10.1111/ijlh.13733] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 09/20/2021] [Accepted: 09/29/2021] [Indexed: 11/27/2022]
Affiliation(s)
- Vanessa Nivaggioni
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Edwin Van Mirre
- CERTE Medical Diagnostics and Advise, Division Clinical Chemistry, Groningen, The Netherlands
| | - Julie Brousseau
- AP-HP, service d'Hématologie Biologique, Hôpital R. Debré, Paris, France
| | - Marie Loosveld
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France.,CNRS, INSERM, CIML, Aix Marseille University, Marseille, France
| |
Collapse
|
14
|
Ait Belkacem I, Mossadegh‐keller N, Bourgoin P, Arnoux I, Loosveld M, Morange P, Markarian T, Michelet P, Busnel JM, Roulland S, Galland F, Malergue F. Cell Analysis from Dried Blood Spots: New Opportunities in Immunology, Hematology, and Infectious Diseases. Adv Sci (Weinh) 2021; 8:e2100323. [PMID: 34278739 PMCID: PMC8456206 DOI: 10.1002/advs.202100323] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 05/03/2021] [Indexed: 05/04/2023]
Abstract
Blood cell analysis is a major pillar of biomedical research and healthcare. These analyses are performed in central laboratories. Rapid shipment from collection site to the central laboratories is currently needed because cells and biomarkers degrade rapidly. The dried blood spot from a fingerstick allows the preservation of cellular molecules for months but entire cells are never recovered. Here leucocyte elution is optimized from dried blood spots. Flow cytometry and mRNA expression profiling are used to analyze the recovered cells. 50-70% of the leucocytes that are dried on a polyester solid support via elution after shaking the support with buffer are recovered. While red blood cells lyse upon drying, it is found that the majority of leucocytes are preserved. Leucocytes have an altered structure that is improved by adding fixative in the elution buffer. Leucocytes are permeabilized, allowing an easy staining of all cellular compartments. Common immunophenotyping and mRNAs are preserved. The ability of a new biomarker (CD169) to discriminate between patients with and without Severe Acute Respiratory Syndrome induced by Coronavirus 2 (SARS-CoV-2) infections is also preserved. Leucocytes from blood can be dried, shipped, and/or stored for at least 1 month, then recovered for a wide variety of analyses, potentially facilitating biomedical applications worldwide.
Collapse
Affiliation(s)
- Ines Ait Belkacem
- Department of Research and DevelopmentBeckman Coulter Life Sciences‐Immunotech130 Avenue de Lattre de TassignyMarseille13009France
- Aix Marseille UniversitéCNRSINSERMCIMLCentre d'Immunologie de Marseille‐LuminyMarseille13009France
| | | | - Penelope Bourgoin
- Department of Research and DevelopmentBeckman Coulter Life Sciences‐Immunotech130 Avenue de Lattre de TassignyMarseille13009France
| | - Isabelle Arnoux
- Department of Hematology LaboratoryTimone University HospitalAPHM264 Rue Saint‐PierreMarseille13005France
| | - Marie Loosveld
- Department of Hematology LaboratoryTimone University HospitalAPHM264 Rue Saint‐PierreMarseille13005France
| | - Pierre‐emmanuel Morange
- Department of Hematology LaboratoryTimone University HospitalAPHM264 Rue Saint‐PierreMarseille13005France
- Aix Marseille UniversitéINSERMINRAEC2VN, 27 Boulevard Jean MoulinMarseille13385France
| | - Thibaut Markarian
- Department of Hematology LaboratoryTimone University HospitalAPHM264 Rue Saint‐PierreMarseille13005France
- Aix Marseille UniversitéINSERMINRAEC2VN, 27 Boulevard Jean MoulinMarseille13385France
| | - Pierre Michelet
- Aix Marseille UniversitéINSERMINRAEC2VN, 27 Boulevard Jean MoulinMarseille13385France
- Department of Emergency Medicine and Intensive CareTimone University HospitalAPHM264 Rue Saint PierreMarseille13005France
| | - Jean Marc Busnel
- Department of Research and DevelopmentBeckman Coulter Life Sciences‐Immunotech130 Avenue de Lattre de TassignyMarseille13009France
| | - Sandrine Roulland
- Aix Marseille UniversitéCNRSINSERMCIMLCentre d'Immunologie de Marseille‐LuminyMarseille13009France
| | - Franck Galland
- Aix Marseille UniversitéCNRSINSERMCIMLCentre d'Immunologie de Marseille‐LuminyMarseille13009France
| | - Fabrice Malergue
- Department of Research and DevelopmentBeckman Coulter Life Sciences‐Immunotech130 Avenue de Lattre de TassignyMarseille13009France
| |
Collapse
|
15
|
Saultier P, Cabantous S, Puceat M, Peiretti F, Bigot T, Saut N, Bordet JC, Canault M, van Agthoven J, Loosveld M, Payet-Bornet D, Potier D, Falaise C, Bernot D, Morange PE, Alessi MC, Poggi M. GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis. J Thromb Haemost 2021; 19:2287-2301. [PMID: 34060193 DOI: 10.1111/jth.15412] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 05/24/2021] [Indexed: 12/11/2022]
Abstract
BACKGROUND GATA1 is an essential transcription factor for both polyploidization and megakaryocyte (MK) differentiation. The polyploidization defect observed in GATA1 variant carriers is not well understood. OBJECTIVE To extensively phenotype two pedigrees displaying different variants in the GATA1 gene and determine if GATA1 controls MYH10 expression levels, a key modulator of MK polyploidization. METHOD A total of 146 unrelated propositi with constitutional thrombocytopenia were screened on a multigene panel. We described the genotype-phenotype correlation in GATA1 variant carriers and investigated the effect of these novel variants on MYH10 transcription using luciferase constructs. RESULTS The clinical profile associated with the p.L268M variant localized in the C terminal zinc finger was unusual in that the patient displayed bleeding and severe platelet aggregation defects without early-onset thrombocytopenia. p.N206I localized in the N terminal zinc finger was associated, on the other hand, with severe thrombocytopenia (15G/L) in early life. High MYH10 levels were evidenced in platelets of GATA1 variant carriers. Analysis of MKs anti-GATA1 chromatin immunoprecipitation-sequencing data revealed two GATA1 binding sites, located in the 3' untranslated region and in intron 8 of the MYH10 gene. Luciferase reporter assays showed their respective role in the regulation of MYH10 gene expression. Both GATA1 variants significantly alter intron 8 driven MYH10 transcription. CONCLUSION The discovery of an association between MYH10 and GATA1 is a novel one. Overall, this study suggests that impaired MYH10 silencing via an intronic regulatory element is the most likely cause of GATA1-related polyploidization defect.
Collapse
Affiliation(s)
- Paul Saultier
- Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
- Department of Pediatric Hematology, Immunology and Oncology, APHM, La Timone Children's Hospital, Marseille, France
| | | | | | | | - Timothée Bigot
- Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | - Noémie Saut
- Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
- APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | | | | | - Johannes van Agthoven
- Structural Biology Program, Division of Nephrology/Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
| | - Marie Loosveld
- APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
- Aix-Marseille Univ, CNRS, INSERM, CIML, Marseille, France
| | | | | | - Céline Falaise
- Department of Pediatric Hematology, Immunology and Oncology, APHM, La Timone Children's Hospital, Marseille, France
- APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | - Denis Bernot
- Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | - Pierre-Emmanuel Morange
- Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
- APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | - Marie-Christine Alessi
- Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
- APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | - Marjorie Poggi
- Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| |
Collapse
|
16
|
Estève C, Roman C, DeLeusse C, Baravalle M, Bertaux K, Blanc F, Bourgeois P, Bresson V, Cano A, Coste ME, Delteil C, Lacoste C, Loosveld M, De Paula AM, Monnier AS, Secq V, Levy N, Badens C, Fabre A. Novel partial loss-of-function variants in the tyrosyl-tRNA synthetase 1 (YARS1) gene involved in multisystem disease. Eur J Med Genet 2021; 64:104294. [PMID: 34352414 DOI: 10.1016/j.ejmg.2021.104294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 06/22/2021] [Accepted: 07/31/2021] [Indexed: 11/19/2022]
Abstract
Cytoplasmic aminoacyl-tRNA synthetases (ARSs) are emerging as a cause of numerous rare inherited diseases. Recently, biallelic variants in tyrosyl-tRNA synthetase 1 (YARS1) have been described in ten patients of three families with multi-systemic disease (failure to thrive, developmental delay, liver dysfunction, and lung cysts). Here, we report an additional subject with overlapping clinical findings, heterozygous for two novel variants in tyrosyl-tRNA synthetase 1 (NM_003680.3(YARS1):c.176T>C; p.(Ile59Thr) and NM_003680.3(YARS1):c.237C>G; p.(Tyr79*) identified by whole exome sequencing. The p.Ile59Thr variant is located in the highly conserved aminoacylation domain of the protein. Compared to subjects previously described, this patient presents a much more severe condition. Our findings support implication of two novel YARS1 variants in these disorders. Furthermore, we provide evidence for a reduced protein abundance in cells of the patient, in favor of a partial loss-of-function mechanism.
Collapse
Affiliation(s)
| | - Céline Roman
- Service de Pédiatrie Multidisciplinaire, Hôpital de La Timone Enfants, APHM, Marseille, France
| | - Cécile DeLeusse
- Service de Pédiatrie Multidisciplinaire, Hôpital de La Timone Enfants, APHM, Marseille, France
| | - Melissa Baravalle
- Service de Pneumologie Pédiatrique, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Karine Bertaux
- CRB TAC (CRB AP-HM TAC), [BIORESOURCES], Marseille, France
| | - Frédéric Blanc
- Service D'Anesthésie Réanimation Pédiatrique, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Patrice Bourgeois
- Aix Marseille Univ, INSERM, MMG, Marseille, France; Service de Génétique Médicale, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Violaine Bresson
- Service D'Urgences Pédiatriques, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Aline Cano
- Service de Pédiatrie Spécialisée & Médecine Infantile, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Marie-Edith Coste
- Service de Pédiatrie Multidisciplinaire, Hôpital de La Timone Enfants, APHM, Marseille, France
| | - Clémence Delteil
- Service de Médecine Légale, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Caroline Lacoste
- Service de Génétique Médicale, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Marie Loosveld
- Laboratoire D'Hématologie Biologique, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - André Maues De Paula
- Laboratoire D'Anatomie Pathologique, Hôpital de La Timone Enfants, APHM, Marseille, France
| | - Anne-Sophie Monnier
- Service de Pédiatrie Multidisciplinaire, Hôpital de La Timone Enfants, APHM, Marseille, France
| | - Véronique Secq
- U1068-CRCM, Aix Marseille Univ, APHM, Hôpital Nord, Service D'anatomo-pathologie, Marseille, France
| | - Nicolas Levy
- Aix Marseille Univ, INSERM, MMG, Marseille, France; Service de Génétique Médicale, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Catherine Badens
- Aix Marseille Univ, INSERM, MMG, Marseille, France; Service de Génétique Médicale, Assistance Publique des Hôpitaux de Marseille, Timone Enfant, Marseille, France
| | - Alexandre Fabre
- Aix Marseille Univ, INSERM, MMG, Marseille, France; Service de Pédiatrie Multidisciplinaire, Hôpital de La Timone Enfants, APHM, Marseille, France.
| |
Collapse
|
17
|
Saultier P, Ninove L, Szepetowski S, Veneziano M, Visentin S, Barlogis V, Saba Villarroel PM, Amroun A, Loosveld M, de Lamballerie X, Chambost H. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. Br J Haematol 2021; 196:e1-e3. [PMID: 34337739 PMCID: PMC8444887 DOI: 10.1111/bjh.17756] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Paul Saultier
- Department of Pediatric Hematology, Immunology, and Oncology, APHM, La Timone Children's Hospital, Marseille, France.,Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Hôpitaux Universitaires de Marseille, Marseille, France
| | - Sarah Szepetowski
- Department of Pediatric Hematology, Immunology, and Oncology, APHM, La Timone Children's Hospital, Marseille, France
| | - Mathilde Veneziano
- Department of Pediatric Hematology, Immunology, and Oncology, APHM, La Timone Children's Hospital, Marseille, France
| | - Sandrine Visentin
- Department of Pediatric Hematology, Immunology, and Oncology, APHM, La Timone Children's Hospital, Marseille, France
| | - Vincent Barlogis
- Department of Pediatric Hematology, Immunology, and Oncology, APHM, La Timone Children's Hospital, Marseille, France
| | - Paola Mariela Saba Villarroel
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Hôpitaux Universitaires de Marseille, Marseille, France
| | - Abdennour Amroun
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Hôpitaux Universitaires de Marseille, Marseille, France
| | - Marie Loosveld
- Laboratory of Hematology, APHM, La Timone Hospital, Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Hôpitaux Universitaires de Marseille, Marseille, France
| | - Hervé Chambost
- Department of Pediatric Hematology, Immunology, and Oncology, APHM, La Timone Children's Hospital, Marseille, France.,Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| |
Collapse
|
18
|
Nozais M, Loosveld M, Pankaew S, Grosjean C, Gentil N, Quessada J, Nadel B, Mionnet C, Potier D, Payet-Bornet D. MYC deficiency impairs the development of effector/memory T lymphocytes. iScience 2021; 24:102761. [PMID: 34258568 PMCID: PMC8259416 DOI: 10.1016/j.isci.2021.102761] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 06/04/2021] [Accepted: 06/18/2021] [Indexed: 11/28/2022] Open
Abstract
In the thymus, T cell progenitors differentiate in order to generate naive T lymphocytes which migrate in the periphery where they will fulfill their function in the adaptive immune response. During thymopoiesis, genomic alterations in thymocytes can promote leukemia development. Among recurrent alteration is PTEN inactivation, which is associated to MYC overexpression. Herein, we used conditional Pten and Myc knockout mouse models and single-cell RNA-sequencing approach, to investigate the impact of MYC loss on physio-pathological development of PTEN-proficient or PTEN-deficient T lymphocytes. First, our results confirm that MYC is mandatory for PTEN loss-mediated leukemogenesis, while it is not required for terminal steps of thymopoiesis. In contrast, we uncovered that Myc ablation in CD4+CD8+ thymocytes disrupts T lymphocytes homeostasis in the spleen, notably by drastically reducing the number of MYC-deficient effector/memory T cells. Collectively, our data show that besides naive T cells proliferation, MYC is essential for effector/memory differentiation. MYC is essential for PTEN loss-mediated T cell leukemogenesis MYC is required for effector/memory T cell differentiation Expansion of splenic CD8+TCRγδ+ cells in MYC-deficient background
Collapse
Affiliation(s)
- Mathis Nozais
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Marie Loosveld
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France.,APHM, Hôpital La Timone, Laboratoire d'Hématologie, Marseille, France
| | - Saran Pankaew
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Clémence Grosjean
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Noémie Gentil
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Julie Quessada
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Bertrand Nadel
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Cyrille Mionnet
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Delphine Potier
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| | - Dominique Payet-Bornet
- Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Parc scientifique de Luminy, Case 906, 13288 Marseille cedex 9, France
| |
Collapse
|
19
|
Quessada J, Cuccuini W, Saultier P, Loosveld M, Harrison CJ, Lafage-Pochitaloff M. Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge. Genes (Basel) 2021; 12:genes12060924. [PMID: 34204358 PMCID: PMC8233729 DOI: 10.3390/genes12060924] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 06/11/2021] [Accepted: 06/14/2021] [Indexed: 01/04/2023] Open
Abstract
Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to morphology, immunophenotyping, germline and somatic cytogenetic and genetic abnormalities. Over recent decades, outcomes have greatly improved, although survival rates remain around 70% and the relapse rate is high, at around 30%. Cytogenetics is an important factor for diagnosis and indication of prognosis. The main cytogenetic abnormalities are referenced in the current WHO classification of acute myeloid leukemia, where there is an indication for risk-adapted therapy. The aim of this article is to provide an updated review of cytogenetics in pediatric AML, describing well-known WHO entities, as well as new subgroups and germline mutations with therapeutic implications. We describe the main chromosomal abnormalities, their frequency according to age and AML subtypes, and their prognostic relevance within current therapeutic protocols. We focus on de novo AML and on cytogenetic diagnosis, including the practical difficulties encountered, based on the most recent hematological and cytogenetic recommendations.
Collapse
Affiliation(s)
- Julie Quessada
- Hematological Cytogenetics Laboratory, Timone Children’s Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), Faculté de Médecine, Aix Marseille University, 13005 Marseille, France;
- Aix Marseille University, CNRS, INSERM, CIML, 13009 Marseille, France;
| | - Wendy Cuccuini
- Hematological Cytogenetics Laboratory, Saint-Louis Hospital, Assistance Publique des Hôpitaux de Paris (APHP), 75010 Paris, France;
- Groupe Francophone de Cytogénétique Hématologique (GFCH), 1 Avenue Claude Vellefaux, 75475 Paris, France
| | - Paul Saultier
- APHM, La Timone Children’s Hospital Department of Pediatric Hematology and Oncology, 13005 Marseille, France;
- Faculté de Médecine, Aix Marseille University, INSERM, INRAe, C2VN, 13005 Marseille, France
| | - Marie Loosveld
- Aix Marseille University, CNRS, INSERM, CIML, 13009 Marseille, France;
- Hematology Laboratory, Timone Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), 13005 Marseille, France
| | - Christine J. Harrison
- Leukaemia Research Cytogenetics Group Translational and Clinical Research Institute, Newcastle University Centre for Cancer Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK;
| | - Marina Lafage-Pochitaloff
- Hematological Cytogenetics Laboratory, Timone Children’s Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), Faculté de Médecine, Aix Marseille University, 13005 Marseille, France;
- Groupe Francophone de Cytogénétique Hématologique (GFCH), 1 Avenue Claude Vellefaux, 75475 Paris, France
- Correspondence: ; Tel.: +33-4-91-38-76-41
| |
Collapse
|
20
|
Saultier P, Loosveld M, Arnoux I, Tosello B, Quessada J, Barlogis V. Bone marrow erythroid cell inclusions reveal congenital erythropoietic porphyria. Br J Haematol 2021; 195:153. [PMID: 34114205 DOI: 10.1111/bjh.17614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Paul Saultier
- Pediatric Hematology, Immunology and Oncology, APHM, Marseille, France.,Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France
| | - Marie Loosveld
- Laboratory of Hematology, APHM, La Timone Hospital, Marseille, France.,Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France
| | - Isabelle Arnoux
- Laboratory of Hematology, APHM, La Timone Hospital, Marseille, France
| | | | - Julie Quessada
- Laboratory of Hematology, APHM, La Timone Hospital, Marseille, France
| | - Vincent Barlogis
- Pediatric Hematology, Immunology and Oncology, APHM, Marseille, France
| |
Collapse
|
21
|
Bourgoin P, Soliveres T, Barbaresi A, Loundou A, Belkacem IA, Arnoux I, Bernot D, Loosveld M, Morange PE, Michelet P, Malergue F, Markarian T. CD169 and CD64 could help differentiate bacterial from CoVID-19 or other viral infections in the Emergency Department. Cytometry A 2021; 99:435-445. [PMID: 33491921 PMCID: PMC8014466 DOI: 10.1002/cyto.a.24314] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 12/15/2020] [Accepted: 12/18/2020] [Indexed: 01/16/2023]
Abstract
The identification of a bacterial, viral, or even noninfectious cause is essential in the management of febrile syndrome in the emergency department (ED), especially in epidemic contexts such as flu or CoVID-19. The aim was to assess discriminative performances of two biomarkers, CD64 on neutrophils (nCD64) and CD169 on monocytes (mCD169), using a new flow cytometry procedure, in patients presenting with fever to the ED during epidemics. Eighty five adult patients presenting with potential infection were included during the 2019 flu season in the ED of La Timone Hospital. They were divided into four diagnostic outcomes according to their clinical records: no-infection, bacterial infection, viral infection and co-infection. Seventy six patients with confirmed SARS-CoV-2 infection were also compared to 48 healthy volunteers. For the first cohort, 38 (45%) patients were diagnosed with bacterial infections, 11 (13%) with viral infections and 29 (34%) with co-infections. mCD169 was elevated in patients with viral infections, with a majority of Flu A virus or Respiratory Syncytial Virus, while nCD64 was elevated in subjects with bacterial infections, with a majority of Streptococcus pneumoniae and Escherichia coli. nCD64 and mCD169 showed 90% and 80% sensitivity, and 78% and 91% specificity, respectively, for identifying patients with bacterial or viral infections. When studied in a second cohort, mCD169 was elevated in 95% of patients with SARS-CoV-2 infections and remained at normal level in 100% of healthy volunteers. nCD64 and mCD169 have potential for accurately distinguishing bacterial and acute viral infections. Combined in an easy and rapid flow cytometry procedure, they constitute a potential improvement for infection management in the ED, and could even help for triage of patients during emerging epidemics.
Collapse
Affiliation(s)
- Pénélope Bourgoin
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France.,Aix Marseille University, INSERM, INRAE, Marseille, France
| | - Thomas Soliveres
- Department of Emergency Medicine and Intensive Care, Timone University Hospital, APHM, Marseille, France
| | - Alexandra Barbaresi
- Department of Emergency Medicine and Intensive Care, Timone University Hospital, APHM, Marseille, France
| | - Anderson Loundou
- Department of Public Health, EA3279 Self-Perceived Health Assessment Research Unit, Timone University Hospital, Aix-Marseille University, Marseille, France
| | - Inès Ait Belkacem
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France.,UMR 7280, Marseille-Luminy Immunology Center (CIML), Marseille, France
| | - Isabelle Arnoux
- Department of Hematology Laboratory, Timone University Hospital, APHM, Marseille, France
| | - Denis Bernot
- Department of Hematology Laboratory, Timone University Hospital, APHM, Marseille, France
| | - Marie Loosveld
- Department of Hematology Laboratory, Timone University Hospital, APHM, Marseille, France
| | - Pierre-Emmanuel Morange
- Aix Marseille University, INSERM, INRAE, Marseille, France.,Department of Hematology Laboratory, Timone University Hospital, APHM, Marseille, France
| | - Pierre Michelet
- Aix Marseille University, INSERM, INRAE, Marseille, France.,Department of Emergency Medicine and Intensive Care, Timone University Hospital, APHM, Marseille, France
| | - Fabrice Malergue
- Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France
| | - Thibaut Markarian
- Aix Marseille University, INSERM, INRAE, Marseille, France.,Department of Emergency Medicine and Intensive Care, Timone University Hospital, APHM, Marseille, France
| |
Collapse
|
22
|
Debliquis A, Baseggio L, Bouyer S, Guy J, Garnache-Ottou F, Genevieve F, Mayeur-Rousse C, Letestu R, Chapuis N, Harrivel V, Bennani H, Lachot S, Loosveld M, Nicolino-Brunet C, Pérès M, Roussel M, Veyrat-Masson R, Jacob MC, Drenou B. Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma. Cytometry B Clin Cytom 2020; 100:488-496. [PMID: 32803917 DOI: 10.1002/cyto.b.21940] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 06/15/2020] [Accepted: 07/15/2020] [Indexed: 02/03/2023]
Abstract
CD30 transmembrane receptor, a member of the tumor necrosis factor receptor family, is expressed in different lymphomas. Brentuximab vedotin (BV), a CD30 monoclonal antibody (Ab)-drug conjugate, is effective in CD30-positive lymphomas. However, the response to BV is not always correlated to CD30 expression detected by immunohistochemistry (IHC). The objectives of this study were to standardize and evaluate CD30 intensity by flow cytometry (FCM) in non-Hodgkin's lymphomas. Twelve centers analyzed 161 cases on standardized cytometers using normalized median fluorescence intensity (nMFI30) of three different Abs, of which one clone can recognize the same epitope as BV. FCM distinguished four groups of cases: negative group (n = 110) which showed no expression with the three clones; high positive group (n = 13) which gave nMFI30 > 5% with all tested clones; dim positive group (n = 17) which showed nMFI30 > 1% with all tested clones and <5% for at least one; discordant group (n = 21) with positive and negative expression of the different clones. In consistency with the literature, CD30 was positive in all anaplastic large cell lymphomas, in some diffuse large B-cell lymphomas (DLBCL), and in other rare lymphomas. FCM results were concordant with those of IHC in 77% of cases. Discrepancies could be explained by clones-related differences, microenvironment, or intracytoplasmic staining. Interestingly, FCM was more sensitive than IHC in 11% of cases, especially in DLBCL. Multicenter standardized FCM of specific CD30 could improve case detection and extend the treatment of BV to various CD30-positive lymphomas.
Collapse
Affiliation(s)
- Agathe Debliquis
- Laboratoire d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France
| | - Lucile Baseggio
- Laboratoire d'Hématologie Cellulaire, Groupement Hospitalier Sud/Hospices Civils de Lyon, Lyon, France
| | - Sabrina Bouyer
- Service d'Hématologie Biologique, Center Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Julien Guy
- Service d'Hématologie biologique, Center Hospitalier Universitaire de Dijon, Dijon, France
| | | | - Franck Genevieve
- Laboratoire d'Hématologie, Center Hospitalier Universitaire d'Angers, Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France
| | - Caroline Mayeur-Rousse
- Laboratoire d'Hématologie, Center Hospitalier Universitaire de Strasbourg, Strasbourg, France
| | - Remi Letestu
- Service d'Hématologie Biologique, Hôpital Avicenne HUPSSD, AP-HP, Bobigny, France
| | - Nicolas Chapuis
- Service d'Hématologie Biologique, Hopital Cochin APHP, Paris, France
| | | | - Hind Bennani
- Laboratoire de biologie, Hopital Foch, Suresnes, France
| | - Sebastien Lachot
- Service d'Hématologie Biologie, Center Hospitalier Universitaire de Tours, Tours, France
| | - Marie Loosveld
- Laboratoire d'Hématologie, Center Hospitalier Universitaire de Marseille, CNRS, INSERM, CIML, Aix Marseille Université, Marseille, France
| | - Corinne Nicolino-Brunet
- Laboratoire d'Hématologie et Biologie Vasculaire du Pr Françoise Dignat George, Center Hospitalier Universitaire La Conception, Marseille, France
| | - Michaël Pérès
- Laboratoire d'Hématologie, IUCT-Oncopole, CHU de Toulouse, Toulouse, France
| | - Mikael Roussel
- Pôle Biologie, Center Hospitalier Universitaire de Rennes, Rennes, France
| | - Richard Veyrat-Masson
- Service d'Hématologie Biologique, Hôpital Estaing, Center Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Marie-Christine Jacob
- Laboratoire d'Immunologie, Center Hospitalier Universitaire de Grenoble-Alpes, La Tronche, France
| | - Bernard Drenou
- Laboratoire d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France
| |
Collapse
|
23
|
Nivaggioni V, Bouriche L, Coito S, Le Floch AS, Ibrahim-Kosta M, Leonnet C, Arnoux I, Loosveld M. Use of Sysmex XN-10 red blood cell parameters for screening of hereditary red blood cell diseases and iron deficiency anaemia. Int J Lab Hematol 2020; 42:697-704. [PMID: 32639680 PMCID: PMC7754411 DOI: 10.1111/ijlh.13278] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 06/04/2020] [Accepted: 06/08/2020] [Indexed: 12/21/2022]
Abstract
Introduction In daily practice in haematology laboratories, red blood cell (RBC) abnormalities are frequent and their management is a real challenge. The aim of this study is to establish a “decision tree” using RBC and reticulocyte parameters from the SYSMEX XN‐10 analyser to distinguish between patients with a hereditary RBC disease from iron deficiency anaemia and other patients. Methods We analysed results of complete RBC counts in a cohort composed of 8217 adults divided into 5 different groups: iron deficiency anaemia (n = 120), heterozygous haemoglobinopathy (n = 92), sickle cell disease syndrome (n = 56), hereditary spherocytosis (n = 18) and other patients (n = 7931). A Classification And Regression Tree (CART) analysis was used to obtain a two‐step decision tree in order to predict these previous groups. Results Five parameters and the calculated RBC score were selected by the CART method: mean corpuscular haemoglobin concentration, percentage of microcytes, distribution width of the RBC histogram, percentage of nucleated red blood cells, immature reticulocytes fraction and finally RBC Score. When applying the tree and recommended flowchart, 158/166 of the RBC hereditary disease patients and 114/120 iron deficiency anaemia patients are detected. Overall, the correct classification rate reached 99.4%. Sensitivity and specificity for RBC disease detection were 95.2% and 99.9%, respectively. These results were confirmed in an independent validation cohort. Conclusion Based on the XN‐10 RBC and reticulocyte parameters, we propose a two‐step decision tree delivering a good prediction and classification of hereditary RBC diseases. These results can be used to optimize additional reticulocyte analysis and microscopy review.
Collapse
Affiliation(s)
- Vanessa Nivaggioni
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | | | | | - Anne-Sophie Le Floch
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Manal Ibrahim-Kosta
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Caroline Leonnet
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Isabelle Arnoux
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Marie Loosveld
- Laboratoire d'Hématologie, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Marseille, France.,Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France
| |
Collapse
|
24
|
Fournier B, Balducci E, Duployez N, Clappier E, Cuccuini W, Arfeuille C, Caye-Eude A, Delabesse E, Bottollier-Lemallaz Colomb E, Nebral K, Chrétien ML, Derrieux C, Cabannes-Hamy A, Dumezy F, Etancelin P, Fenneteau O, Frayfer J, Gourmel A, Loosveld M, Michel G, Nadal N, Penther D, Tigaud I, Fournier E, Reismüller B, Attarbaschi A, Lafage-Pochitaloff M, Baruchel A. B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. Front Oncol 2019; 9:1374. [PMID: 31921638 PMCID: PMC6914849 DOI: 10.3389/fonc.2019.01374] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Accepted: 11/21/2019] [Indexed: 02/03/2023] Open
Abstract
Background: B-cell acute lymphoblastic leukemia associated with t(5;14)(q31;q32); IGH-IL3 is an exceptional cause of eosinophilia. The IGH enhancer on 14q32 is juxtaposed to the IL3 gene on 5q31, leading to interleukin-3 overproduction and release of mature eosinophils in the blood. Clinical, biological and outcome data are extremely scarce in the literature. Except for eosinophilia, no relevant common feature has been highlighted in these patients. However, it has been classified as a distinct entity in the World Health Organization classification. Cases Presentation: Eight patients with t(5;14)(q31;q32) treated by French or Austrian protocols were retrospectively enrolled. Array comparative genomic hybridization, multiplex ligation-dependent probe amplification or genomic PCR search for IKZF1 deletion were performed in 7. Sixteen patients found through an exhaustive search in the literature were also analyzed. For those 24 patients, median age at diagnosis is 14.3 years with a male predominance (male to female ratio = 5). Eosinophilia-related symptoms are common (neurologic in 26%, thromboembolic in 26% or pulmonary in 50%). Median white blood cells count is high (72 × 109/L) and linked to eosinophilia (median: 32 × 109/L). Peripheral blasts are present at a low level or absent (median: 0 × 109/L; range: 0–37 × 109/L). Bone marrow morphology is marked by a low blast infiltration (median: 42%). We found an IKZF1 deletion in 5 out of 7 analyzable patients Outcome data are available for 14 patients (median follow-up: 28 months): 8 died and 6 are alive in complete remission. Some of these features are concordant with those seen in patients with other IGH-rearranged B-cell acute lymphoblastic leukemias: young age at onset, male sex, low blast count, high incidence of IKZF1 deletion and intermediate prognosis. Conclusion: Based on shared epidemiological and biological features, B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32) is a peculiar subset of IGH-rearranged B-cell acute lymphoblastic leukemia with an intermediate prognosis and particular clinical features related to eosinophilia.
Collapse
Affiliation(s)
- Benjamin Fournier
- Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Estelle Balducci
- Hematology Laboratory, University Hospital Paul-Brousse, Assistance Publique des Hôpitaux de Paris (APHP), Villejuif, France
| | | | - Emmanuelle Clappier
- Hematology Laboratory, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Wendy Cuccuini
- Hematology Laboratory, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Chloé Arfeuille
- Department of Genetics, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Aurélie Caye-Eude
- Department of Genetics, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Eric Delabesse
- Department of Haematology, Institut Universitaire de Cancérologie de Toulouse, CHU de Toulouse, Toulouse, France
| | | | - Karin Nebral
- Children's Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Vienna, Austria
| | | | | | - Aurélie Cabannes-Hamy
- Teenagers and Young Adults Hematology Unit, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Florent Dumezy
- Department of Hematology, University Hospital, Lille, France
| | | | - Odile Fenneteau
- Hematology Laboratory, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Jamile Frayfer
- Department of Hematology, Hospital Saint Faron, Meaux, France
| | - Antoine Gourmel
- Department of Pediatric Oncology, Hematology, Immunology, University Hospital of Amiens, Amiens, France
| | - Marie Loosveld
- Hematology Laboratory, Timone Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Aix Marseille University, Marseille, France
| | - Gérard Michel
- Department of Pediatric Hematology, Aix Marseille University, Marseille, France
| | - Nathalie Nadal
- Laboratory of Cytogenetics, University Hospital of Dijon, Dijon, France
| | - Dominique Penther
- Department of Oncology Genetics, Henri Becquerel Center, Rouen, France
| | | | - Elise Fournier
- Department of Hematology, University Hospital, Lille, France
| | - Bettina Reismüller
- Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Andishe Attarbaschi
- Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Marina Lafage-Pochitaloff
- Hematological Cytogenetics Laboratory, Timone Hospital-Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Groupe Francophone de Cytogénétique Hématologique (GFCH), Marseille, France
| | - André Baruchel
- Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.,Institut Universitaire d'Hématologie, EA-3518, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| |
Collapse
|
25
|
Loosveld M, Nivaggioni V, Arnoux I, Bernot D, Michel G, Béné MC, Eveillard M. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia. Cytometry B Clin Cytom 2019; 96:128-133. [PMID: 30734503 DOI: 10.1002/cyto.b.21769] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 01/13/2019] [Accepted: 01/17/2019] [Indexed: 11/06/2022]
Abstract
BACKGROUND In children with acute lymphoblastic leukemia (ALL) low levels of minimal residual disease (MRD) after induction, essentially assessed in the bone marrow, have been shown to be of good prognosis. However, only few studies have tested the peripheral blood for MRD. METHODS Here, we report the impact on survival of peripheral blood (PB) MRD assessment by multiparameter flow cytometry (MFC) at early time points of treatment in 125 B-ALL children, compared to Day 35 molecular bone marrow (BM) MRD. Patients were sampled for MFC one week postdiagnosis after a pre-phase of corticotherapy (Day 8), then after one week of chemotherapy (Day 15). The study enrolled 67 boys and 58 girls with a median follow-up of 52 months. Over the duration of the study, 20 patients relapsed and eight died. MFC was performed based on the leukemia-associated immunophenotype at diagnosis, using panels of 10 antibodies. RESULTS Although, PB MFC-MRD had no prognostic impact at Day 8, Day 15 MRD negativity was associated with a significantly better 4 years DFS (91.6 ± 3% vs. 67.6 ± 9% P = 0.0013). Furthermore, while MFC and molecular data were concordant in most cases, patients with detectable PB MRD on Day 15, yet negative in BM on Day 35 had a significantly lower DFS (P < 0.0001). CONCLUSION This study demonstrates that the less invasive procedure of MFC-MRD assessment in PB can be informative for childhood ALL patients at the early point of Day 15 of the treatment schedule. © 2019 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Marie Loosveld
- APHM, Laboratoire d'Hématologie, Hôpital La Timone, Marseille, France.,CNRS, INSERM, CIML, Aix Marseille University, Marseille, France
| | | | - Isabelle Arnoux
- APHM, Laboratoire d'Hématologie, Hôpital La Timone, Marseille, France
| | - Denis Bernot
- APHM, Laboratoire d'Hématologie, Hôpital La Timone, Marseille, France
| | - Gérard Michel
- APHM, Service d'Hématologie et d'Oncologie Pédiatrique, Hôpital La Timone, Marseille, France
| | - Marie C Béné
- Service d'Hématologie Biologique, CHU Nantes, Nantes, France.,CIRCNA, Nantes, France
| | - Marion Eveillard
- Service d'Hématologie Biologique, CHU Nantes, Nantes, France.,CIRCNA, Nantes, France.,Laboratory Medecine, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
26
|
Bouriche L, Bernot D, Nivaggioni V, Arnoux I, Loosveld M. Detection of Minimal Residual Disease in B Cell Acute Lymphoblastic Leukemia Using an Eight-Color Tube with Dried Antibody Reagents. Cytometry B Clin Cytom 2019; 96:158-163. [PMID: 30698327 DOI: 10.1002/cyto.b.21766] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 12/13/2018] [Accepted: 01/09/2019] [Indexed: 11/12/2022]
Abstract
BACKGROUND Flow cytometry is a powerful tool for the detection of minimal residual disease (MRD) of B cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. However, the staining process and the choice of antibodies rely on laboratory expertise and may be source of variability or technical errors. Recently, Beckman Coulter commercialized a ready to use tube with dried format reagents for BCP-ALL MRD detection. The aim of this study is to evaluate the applicability of this tube and to compare it to a conventional (liquid format reagents) method. METHODS Thirty-one samples from B ALL patients were analyzed: 19 bone marrow (BM) aspirations, 10 peripheral blood (PB) samples and 2 cerebrospinal fluids at different stages of the follow-up. In addition, we tested 5 bone marrow samples mixed into non-pathological (control) bone marrow. The dried format tube included seven antibodies: CD45Kro, CD58FITC, CD34ECD, CD10PC5.5, CD19PC7, CD38AA700, CD20AA750, with possibility of additional antibodies for blast markers identified at diagnosis. For comparison, a liquid format tube was prepared, and considered as the reference. RESULTS This tube was validated for daily routine laboratory, with satisfying qualitative (MRD + or MRD-) and quantitative (MRD percentages) correlation with the reference tube. CONCLUSION With this single dried format tube, we showed interesting results for BCP-ALL MRD detection in the aim of standardization and reliable interlaboratory results. It allows accurate MRD detection including low levels (10-4), and offers possibility to increase performance (supplementary antibody) within a preestablished effective antibody panel for BCP-ALL MRD. © 2018 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Lakhdar Bouriche
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France
| | - Denis Bernot
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France
| | - Vanessa Nivaggioni
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France
| | - Isabelle Arnoux
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France
| | - Marie Loosveld
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France.,CNRS, INSERM, CIML, Aix Marseille University, Marseille, France
| |
Collapse
|
27
|
Gon S, Loosveld M, Crouzet T, Potier D, Bonnet M, Morin SO, Michel G, Vey N, Nunès JA, Malissen B, Roncagalli R, Nadel B, Payet-Bornet D. Fit αβ T-cell receptor suppresses leukemogenesis of Pten-deficient thymocytes. Haematologica 2018; 103:999-1007. [PMID: 29567770 PMCID: PMC6058769 DOI: 10.3324/haematol.2018.188359] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Accepted: 03/15/2018] [Indexed: 12/25/2022] Open
Abstract
Signaling through the αβT cell receptor (TCR) is a crucial determinant of T-cell fate and can induce two opposite outcomes during thymocyte development: cell death or survival and differentiation. To date, the role played by T-cell receptor in the oncogenic transformation of developing T cells remains unclear. Here we show that human primary T-cell acute lymphoblastic leukemias expressing an αβT cell receptor are frequently deficient for phosphatase and tensin homolog protein (PTEN), and fail to respond strongly to T-cell receptor activation. Using Pten-deficient T-cell acute lymphoblastic leukemia mouse models, we confirm that T-cell receptor signaling is involved in leukemogenesis. We show that abrogation of T-cell receptor expression accelerated tumor onset, while enforced expression of a fit transgenic T-cell receptor led to the development of T-cell receptor-negative lymphoma and delayed tumorigenesis. We further demonstrate that pre-tumoral Pten-deficient thymocytes harboring fit T-cell receptors undergo early clonal deletion, thus preventing their malignant transformation, while cells with unfit T-cell receptors that should normally be deleted during positive selection, pass selection and develop T-cell acute lymphoblastic leukemias. Altogether, our data show that fit T-cell receptor signaling suppresses tumor development mediated by Pten loss-of-function and point towards a role of Pten in positive selection.
Collapse
Affiliation(s)
- Stéphanie Gon
- Aix-Marseille Université, CNRS, INSERM, CIML, Marseille, France
| | - Marie Loosveld
- Aix-Marseille Université, CNRS, INSERM, CIML, Marseille, France.,APHM, Hôpital La Timone, Laboratoire d'Hématologie, CRCM, Marseille, France
| | - Thomas Crouzet
- Aix-Marseille Université, CNRS, INSERM, CIML, Marseille, France
| | - Delphine Potier
- Aix-Marseille Université, CNRS, INSERM, CIML, Marseille, France
| | - Mélanie Bonnet
- Aix-Marseille Université, CNRS, INSERM, CIML, Marseille, France
| | - Stéphanie O Morin
- Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Gérard Michel
- APHM, Hôpital La Timone, Service d'Hématologie et d'Oncologie Pédiatrique, Marseille, France
| | - Norbert Vey
- Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.,Institut Paoli-Calmettes, Hematology Department, Marseille, France
| | - Jacques A Nunès
- Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | | | | | - Bertrand Nadel
- Aix-Marseille Université, CNRS, INSERM, CIML, Marseille, France
| | | |
Collapse
|
28
|
Saultier P, Loosveld M, Benoist JF, Michel G. Pancytopenia and megaloblastic erythropoiesis reveal a novel GIF mutation. Br J Haematol 2018; 181:304. [PMID: 29368379 DOI: 10.1111/bjh.15104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Paul Saultier
- Department of Paediatric Haematology and Oncology, APHM, CHU Timone Enfants, Marseille, France.,Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
| | - Marie Loosveld
- CHU Timone, Laboratory of Haematology, APHM, Marseille, France.,Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France
| | | | - Gérard Michel
- Department of Paediatric Haematology and Oncology, APHM, CHU Timone Enfants, Marseille, France
| |
Collapse
|
29
|
Balducci E, Nivaggioni V, Boudjarane J, Bouriche L, Rahal I, Bernot D, Alazard E, Duployez N, Grardel N, Arnoux I, Lafage-Pochitaloff M, Michel G, Nadel B, Loosveld M. Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. Ann Hematol 2017. [DOI: 10.1007/s00277-017-3050-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
30
|
Balducci E, Loosveld M, Rahal I, Boudjarane J, Alazard E, Missirian C, Lafage-Pochitaloff M, Michel G, Zattara H. Interphase FISH for BCR-ABL1
rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1
positive acute lymphoblastic leukemia. Hematol Oncol 2017; 36:344-348. [DOI: 10.1002/hon.2416] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Revised: 02/23/2017] [Accepted: 03/06/2017] [Indexed: 12/20/2022]
Affiliation(s)
- Estelle Balducci
- APHM, Hôpital La Timone; Département de Génétique Médicale; Marseille France
- Aix Marseille Univ; INSERM, GMGF; Marseille France
| | - Marie Loosveld
- APHM, Hôpital La Timone; Laboratoire d'Hématologie; Marseille France
- Aix Marseille Univ; CNRS, INSERM, CIML; Marseille France
| | - Ilhem Rahal
- APHM, Hôpital La Timone; Service d'Hématologie et d'Oncologie Pédiatrique; Marseille France
| | - John Boudjarane
- APHM, Hôpital La Timone; Département de Génétique Médicale; Marseille France
| | - Emilie Alazard
- APHM, Hôpital La Timone; Département de Génétique Médicale; Marseille France
| | - Chantal Missirian
- APHM, Hôpital La Timone; Département de Génétique Médicale; Marseille France
| | - Marina Lafage-Pochitaloff
- APHM, Hôpital La Timone; Département de Génétique Médicale; Marseille France
- Aix Marseille Univ; CNRS, INSERM, CIML; Marseille France
| | - Gérard Michel
- APHM, Hôpital La Timone; Service d'Hématologie et d'Oncologie Pédiatrique; Marseille France
| | - Hélène Zattara
- APHM, Hôpital La Timone; Département de Génétique Médicale; Marseille France
- Aix Marseille Univ; INSERM, GMGF; Marseille France
| |
Collapse
|
31
|
Meunier B, Loosveld M, Grados A, Rico A, Ebbo M, Schleinitz N. Bone marrow erythrophagocytosis and reticulocytopenia in autoimmune haemolytic anaemia. Br J Haematol 2017; 177:346. [PMID: 28369743 DOI: 10.1111/bjh.14568] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Benoit Meunier
- Départment de Medecine Interne, Aix-Marseille Universite, Marseille, France
| | - Marie Loosveld
- Hématologie, Aix-Marseille Universite, Marseille, France
| | - Aurelie Grados
- Départment de Medecine Interne, Aix-Marseille Universite, Marseille, France
| | - Audrey Rico
- Neurologie, Groupe Hospitalier Timone AP-HM, Aix-Marseille Universite, Marseille, France
| | - Mikael Ebbo
- Départment de Medecine Interne, Aix-Marseille Universite, Marseille, France
| | - Nicolas Schleinitz
- Départment de Medecine Interne, Aix-Marseille Universite, Marseille, France
| |
Collapse
|
32
|
Affiliation(s)
- Vanessa Nivaggioni
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France
| | - Aline Cano
- Assistance Publique Hôpitaux de Marseille, Centre de Référence des Maladies Héréditaires du Métabolisme, Marseille, France
| | - Isabelle Arnoux
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France
| | - Gérard Michel
- Assistance Publique Hôpitaux de Marseille, Service d'Hématologie et d'Oncologie Pédiatrique, Hôpital d'Enfants de la Timone, Marseille, France
| | - Marie Loosveld
- Assistance Publique Hôpitaux de Marseille, Laboratoire d'Hématologie, Hôpital de la Timone, Marseille, France. .,Centre d'Immunologie de Marseille Luminy, Aix-Marseille Université, Marseille, France. .,INSERM U1104, Marseille, France. .,CNRS UMR7280, Marseille, France.
| |
Collapse
|
33
|
Arnoux I, Loosveld M. Hepatosplenic T-cell lymphoma: an acute leukemia presentation. Blood 2016; 127:269. [PMID: 27158719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
|
34
|
Eveillard M, Robillard N, Arnoux I, Garand R, Rialland F, Thomas C, Strullu M, Michel G, Béné MC, Fossat C, Loosveld M. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia. Hematol Oncol 2015; 35:237-243. [PMID: 26449287 DOI: 10.1002/hon.2263] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 08/10/2015] [Accepted: 08/28/2015] [Indexed: 11/08/2022]
Abstract
The early persistence of minimal residual disease (MRD) is considered a poor prognostic factor indicative of chemoresistance in acute lymphoblastic leukemia. In French children, chemosensitivity is assessed at day 21 post-induction by cytomorphology. Here, it was investigated whether a more precise evaluation could be obtained at this time point with multiparameter flow cytometry (MFC). This study enrolled 123 children with de novo acute lymphoblastic leukemia. MRD0 was investigated at day 21 in MFC with a combination of antibodies based on the immunophenotype of diagnosis. It was also evaluated at day 35 by immunoglobulin/T-cell receptor quantitative real-time polymerase chain reaction (MRD1). Three risk groups could be delineated based on MRD0. Patients with MFC/MRD0 levels >10-2 (n = 25) were considered high risk, those with levels between 10-2 and 10-4 (n = 46) intermediate risk, and those <10-4 (n = 50) low risk. Overall survival (p = 0.048) and event-free survival (EFS, p = 0.00017) were significantly different between these three groups. EFS of the 14 corticoresistant patients strongly depended on their MRD0 level (p = 0.004). Similarly, both EFS (p = 0.0004) and overall survival (p = 0.02) were significantly different in the 109 chemosensitive patients, according to MRD0 levels. MRD0 and MRD1 levels, compared with 112 patients, were consistent (-/- or +/+) in 57.2% of the cases. Both MRD0+/MRD1+ and MRD0+/MRD1- patients had a significantly worse EFS (p = 0.0001) than those with undetectable MRD at both MRD0 and MRD1. This study confirms the usefulness and superiority of an early point of MRD detection by MFC. In addition, MRD0 in MFC identifies a subgroup of patients with poorer prognosis (MRD0+/MRD1-). Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
| | | | - Isabelle Arnoux
- Hematology Biology, Timone University Hospital, Marseilles, France
| | | | - Fanny Rialland
- Oncopediatrics Department, Nantes University Hospital, France
| | - Caroline Thomas
- Oncopediatrics Department, Nantes University Hospital, France
| | - Marion Strullu
- Oncopediatrics Department, Nantes University Hospital, France
| | - Gérard Michel
- Oncopediatrics Department, Timone University Hospital, Marseilles, France
| | - Marie C Béné
- Hematology Biology, Nantes University Hospital, France
| | - Chantal Fossat
- Hematology Biology, Timone University Hospital, Marseilles, France
| | - Marie Loosveld
- Hematology Biology, Timone University Hospital, Marseilles, France
| |
Collapse
|
35
|
Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y, Payet-Bornet D. Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. Oncotarget 2015; 5:3168-72. [PMID: 24930440 PMCID: PMC4102800 DOI: 10.18632/oncotarget.1873] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
T-ALL patients treated with intensive chemotherapy achieve high rates of remission. However, frequent long-term toxicities and relapses into chemotherapy-refractory tumors constitute major clinical challenges which could be met by targeted therapies. c-MYC is a central oncogene in T-ALL, prompting the exploration of the efficacy of MYC inhibitors such as JQ1 (BET-bromodomain inhibitor), and SAHA (HDAC inhibitor). Using a standardized ex vivo drug screening assay, we show here that JQ1 and SAHA show competitive efficiency compared to inhibitors of proteasome, PI3K/AKT/mTOR and NOTCH pathways, and synergize in combination with Vincristine. We also compared for the first time the in vivo relevance of such associations in mice xenografted with human primary T-ALLs. Our data indicate that although treatments combining JQ1 or SAHA with chemotherapeutic regimens might represent promising developments in T-ALL, combinations will need to be tailored to specific subgroups of responsive patients, the profiles of which still remain to be precisely defined.
Collapse
Affiliation(s)
- Marie Loosveld
- Centre d'Immunologie de Marseille-Luminy, Aix-Marseille Université UM 2, 13288 Marseille, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Loosveld M, Bonnet M, Gon S, Montpellier B, Quilichini B, Navarro JM, Crouzet T, Goujart MA, Chasson L, Morgado E, Picard C, Hernandez L, Fossat C, Gabert J, Michel G, Nadel B, Payet-Bornet D. MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2014; 53:52-66. [DOI: 10.1002/gcc.22117] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
Affiliation(s)
- Marie Loosveld
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
- Department of Hematology; AP-HM La Timone; 13385 Marseille France
| | - Mélanie Bonnet
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | - Stéphanie Gon
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | - Bertrand Montpellier
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | | | - Jean-Marc Navarro
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | - Thomas Crouzet
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | - Marie-Amélie Goujart
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
- Department of Hematology; AP-HM La Timone; 13385 Marseille France
| | - Lionel Chasson
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | - Ester Morgado
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | - Christophe Picard
- UMR 7268; Anthropologie Bio-culturelle; Droit, Ethique et Santé - ADES
| | - Lucie Hernandez
- Hematology Laboratory; AP-HP, Hôpital Saint-Louis 75010 Paris France
| | - Chantal Fossat
- Department of Hematology; AP-HM La Timone; 13385 Marseille France
| | - Jean Gabert
- Université de la Méditerranée IFR 11; Marseille France
- Biochemistry and molecular Biology Laboratory; AP-HM Hopital Nord; Marseille France
| | - Gérard Michel
- Department of Hematology; AP-HM La Timone; 13385 Marseille France
| | - Bertrand Nadel
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| | - Dominique Payet-Bornet
- Centre d'Immunologie de Marseille-Luminy; Aix-Marseille Université; 13288 Marseille France
- INSERM U1104
- CNRS UMR7280; 13288 Marseille France
| |
Collapse
|
37
|
Visentin S, Baudesson de Chanville A, Loosveld M, Chambost H, Barlogis V. La leishmaniose viscérale infantile, une cause de syndrome d’hémophagocytose lympho-histiocytaire facilement curable. Arch Pediatr 2013; 20:1225-1229. [DOI: 10.1016/j.arcped.2013.08.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Accepted: 08/26/2013] [Indexed: 01/19/2023]
|
38
|
Mionnet C, Mondor I, Jorquera A, Loosveld M, Maurizio J, Arcangeli ML, Ruddle NH, Nowak J, Aurrand-Lions M, Luche H, Bajénoff M. Identification of a new stromal cell type involved in the regulation of inflamed B cell follicles. PLoS Biol 2013; 11:e1001672. [PMID: 24130458 PMCID: PMC3794863 DOI: 10.1371/journal.pbio.1001672] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Accepted: 08/22/2013] [Indexed: 01/18/2023] Open
Abstract
Identification of a new stromal cell type in mouse lymph nodes that can be activated by B cells to delineate the transient boundaries of B cell zones during inflammation Lymph node (LN) stromal cells provide survival signals and adhesive substrata to lymphocytes. During an immune response, B cell follicles enlarge, questioning how LN stromal cells manage these cellular demands. Herein, we used a murine fate mapping system to describe a new stromal cell type that resides in the T cell zone of resting LNs. We demonstrated that upon inflammation, B cell follicles progressively trespassed into the adjacent T cell zone and surrounded and converted these stromal cells into CXCL13 secreting cells that in return delineated the new boundaries of the growing follicle. Acute B cell ablation in inflamed LNs abolished CXCL13 secretion in these cells, while LT-β deficiency in B cells drastically affected this conversion. Altogether, we reveal the existence of a dormant stromal cell subset that can be functionally awakened by B cells to delineate the transient boundaries of their expanding territories upon inflammation. Immune responses develop in lymphoid organs such as the tonsils and lymph nodes (LNs), which are composed of leukocytes (95%) and architectural stromal cells (5%). LNs involved in mounting an immune response recruit large numbers of lymphocytes and support the division of those that recognise the foreign antigen, raising the question of how LN stromal cells manage this tremendous remodeling. In this study, we focused on specific zones within the lymph node called germinal centres that comprise dense aggregates or follicles of B lymphocytes, and investigated how lymphoid stromal cells contribute to the reorganization of primary B cell follicles into large reactive secondary follicles. Using a fate mapping system in mice, we identified a new stromal cell type that resides in the T cell zone of noninflamed resting LNs. We demonstrate that upon inflammation, B cells usually contained within B cell follicles progressively trespass into the adjacent T cell zone and surround and convert resident stromal cells into cells that can secrete CXCL13, a B cell chemokine. These CXCL13-secreting cells in turn act to delineate the new transient boundaries of the growing follicle. Identification of this distinct versatile stromal cell type adds to our understanding of mechanisms underlying compartmentalization of lymphoid organs into their functional zones.
Collapse
Affiliation(s)
- Cyrille Mionnet
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
| | - Isabelle Mondor
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
| | - Audrey Jorquera
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
| | - Marie Loosveld
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
| | - Julien Maurizio
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
| | - Marie-Laure Arcangeli
- INSERM, U1068, CRCM, Marseille, France
- CNRS, UMR7258, CRCM, Marseille, France
- Aix-Marseille Univ, F-13284, Marseille, France
- Institut Paoli-Calmettes, Marseille, France
| | - Nancy H. Ruddle
- Yale University School of Medicine, New Haven, Connecticut, United States of America
| | - Jonathan Nowak
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
| | - Michel Aurrand-Lions
- INSERM, U1068, CRCM, Marseille, France
- CNRS, UMR7258, CRCM, Marseille, France
- Aix-Marseille Univ, F-13284, Marseille, France
- Institut Paoli-Calmettes, Marseille, France
| | - Hervé Luche
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
| | - Marc Bajénoff
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France
- Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France
- * E-mail:
| |
Collapse
|
39
|
Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC. Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. JACC Cardiovasc Interv 2013; 6:854-63. [DOI: 10.1016/j.jcin.2013.04.009] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 03/27/2013] [Accepted: 04/11/2013] [Indexed: 12/16/2022]
|
40
|
Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 2013; 111:985-90. [PMID: 23340030 DOI: 10.1016/j.amjcard.2012.12.013] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 12/05/2012] [Accepted: 12/05/2012] [Indexed: 12/21/2022]
Abstract
The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications. A total of 730 patients were included (517 patients treated with clopidogrel 150 mg/day and 213 discharged with prasugrel 10 mg). Platelet reactivity was assessed at 1 month with the platelet reactivity index vasodilator-stimulated phosphoprotein (PRI VASP). High on-treatment platelet reactivity was defined as PRI VASP >50% and low on-treatment platelet reactivity (LTPR) as PRI VASP <20%. The patients were classified according to their genotypes as poor metabolizers (*2/non *17), intermediate metabolizers (*2/*17 or non *2/non *17) and ultrametabolizers (non *2/*17). At 1 month, the prasugrel response was significantly better than the clopidogrel response in all groups of patients, with a lower incidence of high on-treatment platelet reactivity but a greater incidence of LTPR, regardless of the genetic variants. The genetic distribution had a significant effect on the mean PRI VASP values, the incidence of high on-treatment platelet reactivity, and LTPR with both clopidogrel and prasugrel (p <0.05 for all). LTPR identified a group of patients at a greater risk of bleeding (odds ratio 4.8, 95% confidence interval 2.7 to 8.3; p <0.0001). In conclusion, the present study showed that both clopidogrel and prasugrel have genetic modulation by CYP2C19 *2 and *17 alleles and that prasugrel provides greater platelet inhibition, regardless of the genotypes. In addition, LTPR was associated with a greater risk of bleeding.
Collapse
|
41
|
Cuisset T, Gaborit B, Dubois N, Quilici J, Loosveld M, Beguin S, Loundou AD, Moro PJ, Morange PE, Alessi MC, Dutour A, Bonnet JL. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int J Cardiol 2012; 168:523-8. [PMID: 23084816 DOI: 10.1016/j.ijcard.2012.09.214] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Revised: 09/17/2012] [Accepted: 09/27/2012] [Indexed: 11/28/2022]
Abstract
BACKGROUND Diabetes has been identified as a risk factor for impaired clopidogrel response, and these patients might have greater benefit with new P2Y12 blockers such as prasugrel. The present study was designed to assess response to thienopyridine in diabetic patients undergoing PCI for ACS. METHODS AND RESULTS 107 diabetic patients undergoing PCI for ACS were included and treated by clopidogrel 600 mg loading dose and switched to prasugrel 10mg daily after PCI. Platelet reactivity was assessed by PRI VASP. High-on-treatment platelet reactivity (HTPR) was defined by PRI VASP>50% and Low-on-treatment platelet reactivity (LTPR) as PRI VASP below the 75th percentile (PRI VASP<20%). After clopidogrel, mean PRI VASP was 47 ± 21% and 54 patients (50%) were non responders. At one month, mean PRI VASP on prasugrel 10mg daily was 31 ± 13%, 9 patients (8%) had HTPR and 23 patients (22%) had LTPR. In multivariate analysis, factors associated with platelet reactivity were waist circumference for HTPR on clopidogrel and body weight for HTPR and LTPR on prasugrel. 10 patients (9%) suffered from BARC bleeding complications. Patients with bleeding complications had significantly lower PRI VASP values: 22 ± 9 vs. 32 ± 13, p=0.02 and ROC curves identified a cut-off value of VASP=28% to predict bleeding complications. CONCLUSION The present study confirmed that many diabetic patients treated with clopidogrel for ACS have inadequate platelet inhibition. Switch to prasugrel is effective with acceptable safety in this specific population. We observed a significant relationship between on-treatment platelet reactivity and bleeding complications.
Collapse
Affiliation(s)
- Thomas Cuisset
- Département de Cardiologie, CHU Timone, Marseille, F-13385 France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Topalov NN, Yakimenko AO, Canault M, Artemenko EO, Zakharova NV, Abaeva AA, Loosveld M, Ataullakhanov FI, Nurden AT, Alessi MC, Panteleev MA. Two Types of Procoagulant Platelets Are Formed Upon Physiological Activation and Are Controlled by Integrin α
IIb
β
3. Arterioscler Thromb Vasc Biol 2012; 32:2475-83. [DOI: 10.1161/atvbaha.112.253765] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Phosphatidylserine (PS) externalization by platelets upon activation is a key event in hemostasis and thrombosis. It is currently believed that strong stimulation of platelets forms 2 subpopulations, only 1 of which expresses PS.
Methods and Results—
Here, we demonstrate that physiological stimulation leads to the formation of not 1 but 2 types of PS-expressing activated platelets, with dramatically different properties. One subpopulation sustained increased calcium level after activation, whereas another returned to the basal low-calcium state. High-calcium PS-positive platelets had smaller size, high surface density of fibrin(ogen), no active integrin α
IIb
β
3
, depolarized mitochondrial membranes, gradually lost cytoplasmic membrane integrity, and were poorly aggregated. In contrast, the low-calcium PS-positive platelets had normal size, retained mitochondrial membrane potential and cytoplasmic membrane integrity, and combined retention of fibrin(ogen) with active α
IIb
β
3
and high proaggregatory function. Formation of low-calcium PS-positive platelets was promoted by platelet concentration increase or shaking and was decreased by integrin α
IIb
β
3
antagonists, platelet dilution, or in platelets from kindlin-3–deficient and Glanzmann thrombasthenia patients.
Conclusion—
Identification of a novel PS-expressing platelet subpopulation with low calcium regulated by integrin α
IIb
β
3
can be important for understanding the mechanisms of PS exposure and thrombus formation.
Collapse
Affiliation(s)
- Nikolay N. Topalov
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Alena O. Yakimenko
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Matthias Canault
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Elena O. Artemenko
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Natalia V. Zakharova
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Anastasia A. Abaeva
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Marie Loosveld
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Fazoil I. Ataullakhanov
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Alan T. Nurden
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Marie-Christine Alessi
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Mikhail A. Panteleev
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| |
Collapse
|
43
|
Cuisset T, Quilici J, Loosveld M, Gaborit B, Grosdidier C, Fourcade L, Gil JM, Moro PJ, Morange PE, Bonnet JL, Alessi MC. Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. Am Heart J 2012; 164:327-33. [PMID: 22980298 DOI: 10.1016/j.ahj.2012.05.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2012] [Accepted: 05/23/2012] [Indexed: 11/26/2022]
Abstract
BACKGROUND Studies have addressed the benefit of tailored therapy based on initial response to clopidogrel loading dose. However, the appropriate timing for platelet testing remains uncertain. METHODS The present study was performed to compare initial clopidogrel response after 600 mg loading dose and 1-month platelet response and their relationship with ischemic and bleedings events. A total of 475 patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention have been included in the present study. All patients were treated with 600 mg clopidogrel followed by 150 mg daily. Clopidogrel low response was defined by high on-treatment platelet reactivity (HPR) with vasoactive stimulated phosphoprotein >50%, and "hyperresponse," as platelet reactivity index vasoactive stimulated phosphoprotein (PRI VASP) <95th percentile after 600 mg. RESULTS After 600 mg, 210 patients were identified with HPR (44%), and 23 patients (5%), with hyperresponse (PRI VASP <8%). At 1 month on 150 mg clopidogrel daily, 184 patients (39%) had HPR (39%), 14 patients (3 %) had hyperresponse, and mean PRI VASP was significantly lower (43% ± 19% vs 46% ± 21%, P = .04). At 1 month, among the 210 patients with HPR after 600 mg, 127 (60%) remained, whereas among the 265 patients responders after 600 mg, only 57 (22%) remained with HPR (60% vs 22%, P < .0001). Initial response was significantly associated with risk of stent thrombosis and bleeding complications, whereas 1-month assessment was only linked with bleeding events. CONCLUSION In conclusion, the present study showed that initial clopidogrel response in patients with acute coronary syndrome is not a reliable predictor of response to maintenance therapy and their values for prediction of clinical outcome are likely to be different.
Collapse
|